Health Robotics expands CytoCare market into Spain and Portugal
26 July 2010
Health Robotics has announced it has granted exclusive rights
to Grifols S.A. to distribute its CytoCare chemotherapy system in Spain
and Portugal, and signed an agreement to to install the first-ever
Cancer Therapy Robot in Spain at Vall d'Hebron University Hospital in
Barcelona in November 2010.
"We are very excited to have been selected by Health Robotics as
their long-term exclusive CytoCare partner in Spain and Portugal,
adding the Cancer Therapy Robot in our core Iberian peninsula market
to our prior i.v.STATION distribution rights.
Xavier Guix, Vice President of Marketing for Grifols' Hospital
System Division, said, "CytoCare, the world's first and only robotic
system designed for the safe and sterile preparation of
patient-specific hazardous IV Admixtures, represents an ideal
complement to our other market-leading Pharmacy Automation products.
Vall d'Hebron University Hospital has demonstrated a long trajectory
of innovation, utilizing new technologies to achieve excellent
peer-reviewed and published efficiency and medication safety
results, with prestigious awards such as Best European Pharmacy
Management, ESADE's Management Innovation, and finally the Best
Health Care Ideas in 2009."
Health Robotics' CEO Werner Rainer said, "It is very exciting to
expand our i.v.STATION relationship at such a prestigious hospital
as Vall d'Hebron University Hospital, with its world-renowned cancer
research program and the well-documented scientific publications by
Dr. Josep Monterde and his team of scientists and pharmacists.
We feel rewarded with this new contract after 1,000 Bed Bolzano
General Hospital hosted an inspection team from Vall d'Hebron
University Hospital in order to ascertain CytoCare's speed,
flexibility, and safety in comparison with other IV Robotics
companies, and demonstrating that CytoCare handled 70% of Chemo IV
doses within a 4 hour time-window.
"Additionally, Grifols is the perfect fit for CytoCare in Spain
and Portugal due to its well-established distribution channels,
commitment to patient safety, its company stability and superior
market footprint, and finally its world-class service
infrastructure. In addition to the obvious success in expanding our
partnership with Grifols and receiving a repeat endorsement from an
existing Health Robotics' partner, I'm very pleased that this new
contract symbolizes the first CytoCare installation in Spain, and
the eight European Union member country to embrace CytoCare for its
Oncology Therapy Compounding needs."